To investigate BCG tolerability and response with respect to timing of BCG administration following TUR in patients with non-muscle invasive bladder cancer (NMIBC). A review of NMIBC patients at our institution managed with at least ‘adequate BCG’ (defined by the US FDA as at least 5/6 induction instillations with 2 additional instillations comprising either maintenance […]
Low-grade upper tract urothelial carcinoma (UTUC) comprises a substantial percentage of UTUCs. While mortality risk is low, diagnostic choices, therapeutic care, and continued management of these carcinomas are complex decisions. Low-grade UTUC can cause hematuria and urinary obstruction, and tumors tend to recur. Periodic radiographic imaging is required as well as ureteroscopic interventions not only to […]
Prostate cancer is associated with an immunosuppressive tumor microenvironment, including relatively low tumor mutational burden (TMB), increased activity of myeloid-derived suppressor cells (MDSCs) and regulatory T cells, and defects in major histocompatibility complex (MHC) class I expression and interferon (IFN)-1 signaling. As a result, immuno-oncology approaches for the treatment of metastatic prostate cancer have previously […]
Gene expression profiling has successfully classified muscle-invasive bladder cancer (MIBC) tumors into distinct categories that differ in their genetic characteristics and tumor mutation burden (TMB). In addition to cancer-cell autonomous factors, the tumor microenvironment (TME) is a known key player in therapy response. The relationship between TME and different MIBC molecular subtypes is understudied.
Huntsman Cancer Institute at the University of Utah (U of U) announced the appointment of Neeraj Agarwal, MD, physician-scientist at HCI and professor of internal medicine at the U of U, as senior director of clinical research innovation. In this role, Agarwal will serve on the senior leadership of the Comprehensive Cancer Center at HCI. He will oversee critical […]
Introduction Cancers of the kidney and renal pelvis (when considered in aggregate despite different histology) represent the 6th most common newly diagnosed tumors in men and 8th most common in women in the United States in 20201, representing an estimated 73,750 new diagnoses and 14,830 deaths. The vast majority of these cancers will be renal parenchymal tumors […]
Interleukin (IL)‐10 has anti‐inflammatory and CD8+ T‐cell‐stimulating properties. Pegilodecakin (pegylated recombinant human IL‐10) induces intratumoral antigen‐specific CD8 + T‐cells and upregulates IFNγ and major histocompatibility complexes (MHC) I and II. Pegilodecakin has single‐agent activity with manageable toxicity in advanced renal cell carcinoma (aRCC) (data cutoff 24 March 2016). Pegilodecakin with pembrolizumab or nivolumab revealed clinical activity in […]
The European Urological Scholarship Programme (EUSP) recently redesigned its two scholarship programmes Clinical Visit and 1-Year Scholarship in order for young urologists to still refine their skills in the time of the pandemic but this time, at certified leading institutions in their own countries. The Clinical Visit programme will offer scholars observership and opportunities to […]
{{header-clinical-trials-navigation}} Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (Padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer Condition: Transitional Cell Cancer of Renal Pelvis and Ureter Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT04620239 Sponsor: Steba Biotech S.A. Phase: Phase 3 Eligibility: […]
The European Association of Urology risk stratification dichotomizes patients with upper tract urothelial carcinoma (UTUC) into two risk categories. To evaluate the predictive value of a new classification to better risk stratify patients eligible for kidney-sparing surgery (KSS).
